fda deadline for compounded semaglutide ends shortage, closing the door on Wegovy, Ozempic FDA sets tirzepatide compounding deadlines

Retatrutides triple-action approach makes it different from other weight loss treatments

PMID: 240 SylvesterFA

Obesity is one of the greatest threats to health because of the elevated risk of type 2 diabetes mellitus , hypertension, cardiovascular diseases and cancer

The Diabetes Prevention Program demonstrated that intensive lifestyle interventiontargeting 7% weight loss through reduced caloric intake (1200-1800 kcal/day based on initial weight) and 150 minutes weekly of moderate physical activityreduced type 2 diabetes incidence by 58% over three years

Conclusion Unquestionably, GLP-1 agonist drugs are trending, and that trend shows no sign of slowing down anytime soon